Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19
et al., J Endocrinol. Invest., doi:10.1007/s40618-021-01535-2
, Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients.., J Endocrinol. Invest., doi:10.1007/s40618-021-01535-2
Retrospective 348 hospitalized patients in Italy showing vitamin D deficiency associated with acute hypoxemic respiratory failure. Vitamin D supplementation during hospitalization was not significantly associated with mortality or ventilation.
|
risk of death, 19.0% lower, OR 0.81, p = 0.49, treatment 116, control 232, supplementation, RR approximated with OR.
|
|
risk of mechanical ventilation, 67.0% higher, OR 1.67, p = 0.08, treatment 116, control 232, supplementation, RR approximated with OR.
|
|
risk of death, 2.4% lower, RR 0.98, p = 0.91, high D levels 187, low D levels 161, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >12ng/mL, control prevalance approximated with overall prevalence, outcome based on serum levels.
|
|
risk of acute hypoxemic respiratory failure, 37.0% lower, RR 0.63, p = 0.006, high D levels 72 of 187 (38.5%), low D levels 97 of 161 (60.2%), NNT 4.6, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >12ng/mL, outcome based on serum levels.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Mazziotti et al., 5 Mar 2021, retrospective, Italy, peer-reviewed, 11 authors, dosage varies.
Abstract: Journal of Endocrinological Investigation (2021) 44:2285–2293
https://doi.org/10.1007/s40618-021-01535-2
ORIGINAL ARTICLE
Vitamin D deficiency, secondary hyperparathyroidism and respiratory
insufficiency in hospitalized patients with COVID‑19
G. Mazziotti1,2 · E. Lavezzi2 · A. Brunetti1,2 · M. Mirani2 · G. Favacchio2 · A. Pizzocaro2 · M. T. Sandri3 · A. Di Pasquale4 ·
A. Voza5 · M. Ciccarelli4 · A. G. Lania1,2 · Humanitas COVID19 Task Force
Received: 4 January 2021 / Accepted: 11 February 2021 / Published online: 5 March 2021
© Italian Society of Endocrinology (SIE) 2021
Abstract
Purpose Hypovitaminosis D has emerged as potential risk factor for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection in the general population with variable effects on the outcome of the coronavirus disease-19 (COVID-19).
The aim of this retrospective single-center study was to investigate the impact of hypovitaminosis D and secondary hyperparathyroidism on respiratory outcomes of COVID-19.
Methods Three-hundred-forty-eight consecutive patients hospitalized for COVID-19 at the IRCCS Humanitas Research
Hospital, Rozzano, Milan (Italy) were evaluated for arterial partial pressure oxygen (PaO2)/fraction of inspired oxygen
(FiO2) ratio, serum 25hydroxy-vitamin D [25(OH)D], parathyroid hormone (PTH) and inflammatory parameters at study
entry and need of ventilation during the hospital stay.
Results In the entire population, vitamin D deficiency (i.e., 25(OH)D values < 12 ng/mL) was significantly associated with
acute hypoxemic respiratory failure at the study entry [adjusted odds ratio (OR) 2.48, 95% confidence interval 1.29–4.74;
P = 0.006], independently of age and sex of subjects, serum calcium and inflammatory parameters. In patients evaluated for
serum PTH (97 cases), secondary hyperparathyroidism combined with vitamin D deficiency was significantly associated with
acute hypoxemic respiratory failure at study entry (P = 0.001) and need of ventilation during the hospital stay (P = 0.031).
Conclusion This study provides evidence that vitamin D deficiency, when associated with secondary hyperparathyroidism,
may negatively impact the clinical outcome of SARS-CoV-2-related pneumonia.
Keywords PTH · Vitamin D · Hyperparathyroidism · Vitamin D deficiency · COVID-19 · SARS-CoV-2 infection ·
Pneumonia
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.